Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus

We present a five-year-old boy with facial angiofibromas associated to tuberous sclerosis successfully treated with topical sirolimus 0.4% applied three times a week for six months. After six months we observed a nearly complete resolution of facial angiofibromas. The blood levels of sirolimus remai...

Full description

Saved in:
Bibliographic Details
Published inUgeskrift for læger Vol. 175; no. 43; p. 2569
Main Authors Tiedemann Svendsen, Mathias, Bygum, Anette, Hansen, Lars Kjærsgaard, Broesby-Olsen, Sigurd
Format Journal Article
LanguageDanish
Published Denmark 21.10.2013
Subjects
Angiofibroma - drug therapy
Angiofibroma - etiology
Angiofibroma - pathology
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - therapeutic use
Child, Preschool
Facial Neoplasms - drug therapy
Facial Neoplasms - etiology
Facial Neoplasms - pathology
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - therapeutic use
Male
Ointments - therapeutic use
Sirolimus - administration & dosage
Sirolimus - therapeutic use
Treatment Outcome
Tuberous Sclerosis - complications
Online AccessGet more information

Cover

More Information
Summary:We present a five-year-old boy with facial angiofibromas associated to tuberous sclerosis successfully treated with topical sirolimus 0.4% applied three times a week for six months. After six months we observed a nearly complete resolution of facial angiofibromas. The blood levels of sirolimus remained under a detectable limit and no side-effects were observed. Topically applied sirolimus seems to be a safe and effective alternative to surgery or laser therapy.
ISSN:1603-6824